Phase III trial of Padcev meets primary endpoint in urothelial cancer.- Astellas Pharma and Seattle Genetics

Astellas Pharma and Seattle Genetics announced that a phase III trial of Padcev (enfortumab vedotin-ejfv) met its primary endpoint of overall survival compared to chemotherapy for previously treated locally advanced or metastatic Urothelial Cancer. The results were reviewed by an independent Data Monitoring Committee following a planned interim analysis. The global EV-301 clinical trial compared Padcev to chemotherapy in adult patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy and a PD-1/L1 inhibitor. In the trial, Padcev significantly improved overall survival (OS), with a 30 percent reduction in risk of death (Hazard Ratio [HR]=0.70; [95% Confidence Interval (CI): 0.56, 0.89]; p=0.001). Padcev also significantly improved progression-free survival (PFS), a secondary endpoint, with a 39 percent reduction in risk of disease progression or death (HR=0.61 [95% CI: 0.50, 0.75]; p<0.00001). for patients in the padcev arm of the trial, adverse events were consistent with those listed in the u.s. prescribing information, with rash, hyperglycemia, decreased neutrophil count, fatigue, anemia and decreased appetite as the most frequent grade 3 or greater adverse event(s) occurring in more than 5 percent of patients. data from ev-301 will be submitted for presentation at an upcoming scientific congress. patients in the chemotherapy arm of the trial will be offered the opportunity to receive padcev. the results will be submitted to the u.s. food and drug administration (fda) as the confirmatory trial following the drug's accelerated approval in 2019. ev-301 is also intended to support global registrations.>